BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC) Files An 8-K Other Events
Item 8.01 Other Events

On February 16, 2018, the Company filed a Current Report on Form 8-K (the “Original Filing”) providing the time and place of the Company’s 2018 annual meeting of stockholders (the “Annual Meeting”) as well as the record date for the Annual Meeting. This amendment to the Original Filing is being filed for the purpose of correcting a scrivener’s error with regard to the record date for the Annual Meeting, and should be read in conjunction with the Original Filing. The record date for the Annual Meeting will be April 20, 2018. All stockholders of record as of April 20, 2018 will be entitled to vote at the Annual Meeting.

2

About BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC)

BioSpecifics Technologies Corp. (BioSpecifics) is a biopharmaceutical company. The Company is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. The Company has a development and license agreement with Endo International plc (Endo) for injectable collagenases for marketed indications and indications in development. CCH is marketed as XIAFLEX and as XIAPEX in Europe. Its injectable collagenases are marketed for indications, such as Dupuytren’s contracture and Peyronie’s disease. BioSpecifics is conducting development work with respect to human lipoma and uterine fibroids. XIAFLEX and XIAPEX are approved in the United States, the European Union, Switzerland, Canada, Australia and Japan for the treatment of Dupuytren’s contracture. Endo manages the research and development of XIAFLEX for their licensed indications, including frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis and uterine fibroids.